Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00184054 | Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia | terminated | Phase 2 | 11 | University of Southern CaliforniaOTHER | 1 | Jul 25, 2014 | clinicaltrials |
| NCT00002621 | Interferon Alfa in Treating Children With HIV-Related Cancer | completed | Phase 2 | 8 | Children's Oncology GroupNETWORK | 4 | Jul 24, 2014 | clinicaltrials |
| NCT00002785 | Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia | completed | Phase 2 | — | Children's Oncology GroupNETWORK | 3 | Jul 24, 2014 | clinicaltrials |
| NCT00002805 | Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 115 | Children's Oncology GroupNETWORK | 3 | Jul 24, 2014 | clinicaltrials |
| NCT00003735 | Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 11 | Children's Oncology GroupNETWORK | 3 | Jul 24, 2014 | clinicaltrials |
| NCT00433745 | Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy | completed | Phase 2 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 8, 2014 | clinicaltrials |
| NCT02182596 | DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML(MYLOFRANCE2) | completed | Phase 1 / Phase 2 | 20 | Acute Leukemia French AssociationOTHER | 1 | Jul 8, 2014 | clinicaltrials |
| NCT01557777 | Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 17 | AbbVie (prior sponsor, Abbott)INDUSTRY | 5 | Jul 4, 2014 | clinicaltrials |
| NCT00669318 | Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 41 | Mayo ClinicOTHER | 1 | Jul 1, 2014 | clinicaltrials |
| NCT00415909 | TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2014 | clinicaltrials |
| NCT00955916 | CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML) | completed | Phase 2 | 38 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 27, 2014 | clinicaltrials |
| NCT02103322 | Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions | completed | Phase 2 / Phase 3 | 48 | Amneal Pharmaceuticals, LLCINDUSTRY | 1 | Jun 27, 2014 | clinicaltrials |
| NCT00076401 | A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 27 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 26, 2014 | clinicaltrials |
| NCT00754650 | A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia | completed | Phase 2 | 2 | Hoffmann-La RocheINDUSTRY | 1 | Jun 26, 2014 | clinicaltrials |
| NCT01354457 | Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+(RIT 90YEpra) | unknown | Phase 1 / Phase 2 | 21 | Nantes University HospitalOTHER | 1 | Jun 25, 2014 | clinicaltrials |
| NCT00947648 | Outpatient Neutropenic Diet Study | terminated | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 13, 2014 | clinicaltrials |
| NCT01236144 | A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.(AML18 Pilot) | completed | Phase 1 / Phase 2 | 113 | Cardiff UniversityOTHER | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00176462 | CINJALL: Treatment for Children With Acute Lymphocytic Leukemia | completed | Phase 2 | 60 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00349349 | HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab | completed | Phase 2 | 223 | GlaxoSmithKlineINDUSTRY | 0 | Jun 4, 2014 | clinicaltrials |
| NCT00580034 | Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath | completed | Phase 2 | 176 | David Rizzieri, MDOTHER | 1 | Jun 3, 2014 | clinicaltrials |
| NCT00597714 | Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | completed | Phase 2 | 264 | David Rizzieri, MDOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00096122 | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | May 26, 2014 | clinicaltrials |
| NCT00100711 | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 27 | Pharmacyclics LLC.INDUSTRY | 1 | May 23, 2014 | clinicaltrials |
| NCT00290472 | CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 2 | 89 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00183950 | Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy | terminated | Phase 1 / Phase 2 | 12 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00184041 | Intensified Post Remission Therapy Containing PEG-Asparaginase | completed | Phase 2 | 47 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00941928 | Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00098670 | Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00305773 | Vorinostat in Treating Patients With Acute Myeloid Leukemia | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | May 19, 2014 | clinicaltrials |
| NCT00701766 | BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia | completed | Phase 2 | 71 | Boehringer IngelheimINDUSTRY | 2 | May 16, 2014 | clinicaltrials |
| NCT00398112 | Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00290810 | Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00303966 | Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 7, 2014 | clinicaltrials |
| NCT00909168 | Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)(MYFLAI07) | completed | Phase 2 / Phase 3 | 130 | University Hospital, Udine, ItalyOTHER | 1 | May 6, 2014 | clinicaltrials |
| NCT00003340 | Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia | completed | Phase 2 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 2, 2014 | clinicaltrials |
| NCT00003572 | Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers | completed | Phase 2 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 2, 2014 | clinicaltrials |
| NCT00003960 | Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 2 | 36 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 2, 2014 | clinicaltrials |
| NCT00130702 | Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia | completed | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | May 1, 2014 | clinicaltrials |
| NCT01542684 | Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2014 | clinicaltrials |
| NCT00003961 | Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome | completed | Phase 2 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 17, 2014 | clinicaltrials |
| NCT00011934 | Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia | completed | Phase 2 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 17, 2014 | clinicaltrials |
| NCT00276601 | Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia | completed | Phase 2 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 17, 2014 | clinicaltrials |
| NCT00315705 | A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias. | completed | Phase 1 / Phase 2 | 50 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 14, 2014 | clinicaltrials |
| NCT00373529 | A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II) | completed | Phase 2 | 116 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 14, 2014 | clinicaltrials |
| NCT02113319 | Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia(DasaCBF) | completed | Phase 2 | 27 | University Hospital, AngersOTHER_GOV | 1 | Apr 14, 2014 | clinicaltrials |
| NCT01193400 | Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years | terminated | Phase 2 | 75 | PETHEMA FoundationOTHER | 1 | Apr 7, 2014 | clinicaltrials |
| NCT01246557 | Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment(LENDEX-LLC-09) | completed | Phase 1 / Phase 2 | 20 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | Apr 4, 2014 | clinicaltrials |
| NCT00949117 | Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer | terminated | Phase 2 | 9 | University of South FloridaOTHER | 0 | Apr 2, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jul 25, 2014source: clinicaltrials